Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 8 5 versus HEPATASOL 8.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 8 5 versus HEPATASOL 8.
AMINOSYN 8.5% vs HEPATASOL 8%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 8.5% is a crystalline amino acid solution that provides a source of nitrogen and essential/non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance. It serves as a substrate for metabolic pathways, including gluconeogenesis and ketogenesis, and supports immune function and enzyme production.
HEPATASOL 8% (amino acid injection) provides essential and non-essential amino acids to support protein synthesis and correct nitrogen balance in hepatic encephalopathy. It reduces plasma ammonia levels by promoting urea cycle activity and decreasing aromatic amino acids.
Intravenous infusion: 1.0-1.5 g amino acids/kg/day (11.8-17.6 mL/kg/day of 8.5% solution) via central line; rate not to exceed 0.1 g amino acids/kg/hour.
Intravenous infusion of 500 mL (40 g amino acids) over 3-4 hours, administered once daily or as directed by clinical response.
None Documented
None Documented
Variable; amino acids have rapid distribution and metabolic half-lives of minutes to hours; terminal half-life of infused amino acid mixtures is approximately 1–2 hours for most components in patients with normal hepatic function
Approximately 30-60 minutes for individual amino acids; clinical context: rapid clearance supports continuous infusion to maintain plasma levels.
Renal elimination of infused amino acids as urea, ammonia, and other nitrogenous waste products; minimal biliary/fecal excretion (<2%)
Renal: >95% of administered amino acids are reabsorbed and metabolized; negligible unchanged excretion. Biliary/fecal: <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution